Email :
info@xynomicpharma.com
Latest News
Y. Mark Xu talks with CGTN (China Global TV Network)
Mark Xu, Founder, Chairman, Chief Executive Officer and President of Xynomic talks with CGTN “The Point with Liu Xin” and provides insight regarding the current trend of the price of cancer drugs in China. “The
Details
Xynomic Pharma Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma
September 23, 2019 06:00 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. SHANGHAI, Sept. 23, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today
Details
Xynomic Pharma Doses First Chinese Patient in Pivotal Phase 3 Kidney Cancer Trial and Hires Medical Monitor
September 13, 2019 15:58 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. SHANGHAI, Sept. 13, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today
Details
Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors
August 30, 2019 08:41 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details
Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors
August 30, 2019 08:41 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details
Xynomic Research Institute Has Successfully Designed a Series of Potent RET Kinase Inhibitors
August 16, 2019 16:30 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 16, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details
Xynomic Pharma Receives Important Accreditation from Independent Ethics Committees of Leading Chinese Cancer Hospitals
August 07, 2019 16:00 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 07, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details
Xynomic Filed Fast-Track Designation Application for Follicular Lymphoma Treatment with the U.S. FDA
August 01, 2019 07:00 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, Aug. 01, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage U.S.-China oncology drug
Details
Xynomic Received China Approval to Start 2 Pivotal Lymphoma Clinical Trials
July 30, 2019 07:00 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, July 30, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug
Details
Xynomic Pharma Will Present at 3rd World-China Immunotherapy & Gene Therapy Congress
July 26, 2019 12:29 ET | Source: Xynomic Pharmaceuticals Holdings, Inc. RALEIGH, N.C. and SHANGHAI, July 26, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage U.S.-China oncology drug
Details
Xynomic Completes Pre-IND Meeting with US FDA for XP-102, a Novel Pan-RAF Inhibitor against Colorectal Cancer and Lung Cancer
RALEIGH, N.C. and SHANGHAI, June 12, 2019 (GLOBE NEWSWIRE) — Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company, announced that it recently held a pre-IND meeting with the
Details